(0.20%) 5 142.00 points
(0.21%) 38 521 points
(0.28%) 17 897 points
(-0.57%) $83.37
(1.98%) $1.961
(-0.04%) $2 346.20
(0.28%) $27.61
(0.91%) $930.45
(-0.23%) $0.933
(-0.28%) $10.99
(-0.33%) $0.798
(1.07%) $92.86
@ $0.897
発行日: 15 2月 2024 @ 05:28
リターン: -34.84%
前回のシグナル: 2月 15 - 00:42
前回のシグナル:
リターン: -0.39 %
Live Chart Being Loaded With Signals
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States...
Stats | |
---|---|
本日の出来高 | 176 491 |
平均出来高 | 554 766 |
時価総額 | 4.28M |
EPS | $0 ( 2024-04-04 ) |
次の収益日 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.120 |
ATR14 | $0.0100 (1.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-02 | Gower Bob G | Buy | 90 287 | Common Stock |
2023-03-01 | Gower Bob G | Buy | 270 000 | Common Stock |
2023-02-28 | Gower Bob G | Buy | 109 300 | Common Stock |
2022-12-09 | Gower Bob G | Buy | 357 143 | Common Stock |
2022-12-09 | Gower Bob G | Buy | 714 286 | Warrants |
INSIDER POWER |
---|
99.26 |
Last 80 transactions |
Buy: 23 095 136 | Sell: 3 675 006 |
ボリューム 相関
Ensysce Biosciences, Inc. 相関
10 最も負の相関 | |
---|---|
NETE | -0.92 |
LWAC | -0.92 |
MDRRP | -0.916 |
SRAC | -0.904 |
WSBCP | -0.895 |
RAVN | -0.889 |
HNST | -0.889 |
OVBC | -0.886 |
MRBK | -0.885 |
MNSBP | -0.883 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ensysce Biosciences, Inc. 相関 - 通貨/商品
Ensysce Biosciences, Inc. 財務諸表
Annual | 2023 |
収益: | $2.23M |
総利益: | $-5.36M (-240.17 %) |
EPS: | $-4.69 |
FY | 2023 |
収益: | $2.23M |
総利益: | $-5.36M (-240.17 %) |
EPS: | $-4.69 |
FY | 2022 |
収益: | $2.52M |
総利益: | $-17.31M (-686.08 %) |
EPS: | $-138.73 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-29.60 |
Financial Reports:
No articles found.
Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。